MKGAF - MERCK Kommanditgesellschaft auf Aktien

Other OTC - Other OTC Delayed Price. Currency in USD
106.05
-1.75 (-1.62%)
At close: 3:38PM EDT
Stock chart is not supported by your current browser
Previous Close107.80
Open105.95
Bid0.00 x 0
Ask0.00 x 0
Day's Range105.23 - 106.20
52 Week Range94.40 - 115.70
Volume58,869
Avg. Volume1,150
Market Cap45.955B
Beta (3Y Monthly)0.65
PE Ratio (TTM)20.47
EPS (TTM)5.18
Earnings DateN/A
Forward Dividend & Yield1.49 (1.31%)
Ex-Dividend Date2018-04-30
1y Target EstN/A
Trade prices are not sourced from all markets
  • GuruFocus.com2 days ago

    Keeley Funds Comments on Versum Materials

    Guru stock highlight

  • Reuters5 days ago

    UPDATE 2-European shares hit by U.S. tariff threat, growth jitters (April 9)

    European shares slid on Tuesday, with most sectors falling after the United States threatened to slap tariffs on goods from the European Union, with worries compounded by the IMF cutting its global growth forecast. The U.S. Trade Representative proposed a list of European Union products late on Monday on which to slap tariffs in retaliation to more than $11 billion of EU subsidies to Airbus the World Trade Organization has found cause "adverse effects" to the United States.

  • Benzinga8 days ago

    Merck KGaA Signs Versum Buyout Deal; Entegris Receives Termination Payment

    The business combination received unanimous approval from the boards of the German pharmaceutical company and Versum, Merck said in a Friday press release. Versum is a supplier of process chemicals, gases and semiconductor manufacturing equipment.

  • Reuters8 days ago

    Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals

    Germany's Merck KGaA sealed a $6.5 billion (4.9 billion pounds) takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris. A bet on a recovery in electronic materials markets for semiconductor makers, the transaction will boost the share of profit that diversified Merck derives from high-tech chemicals to 27 percent from 19 percent previously. Merck, also maker of pharmaceuticals and biotech production gear, this week won the backing of Versum's board for its $53-per-share offer, lifted from $48 previously, having been spurned for weeks.

  • Benzinga12 days ago

    Versum Materials Says Revised Merck KGaA Buyout Proposal 'Superior' To Entegris Offer

    Versum Materials, Inc . (NYSE: VSM ) announced Monday that it received a revised proposal from Merck KGaA to acquire Versum for $53 per share, up from Merck's prior $48-per-share proposal on Feb. 27.  ...

  • Merck KGaA wins Versum's support for sweetened $6.5 billion offer
    Reuters12 days ago

    Merck KGaA wins Versum's support for sweetened $6.5 billion offer

    Merck KGaA won the backing of Versum's board for a sweetened $6.5 billion takeover proposal, overturning an agreed merger with rival Entegris as it bets on a recovery in electronic materials markets. "This proposal constitutes a 'Superior Proposal' as defined in Versum's previously announced merger agreement with Entegris, Inc.," Versum said in a statement on Monday. On a per share basis, Germany's Merck offered $53, up from $48 previously, after reviewing business data and following meetings between Merck Chief Executive Stefan Oschmann and Versum Chairman Seifi Ghasemi, filings showed.

  • Financial Times12 days ago

    Merck wins takeover battle for Versum with $6.4bn offer 

    Versum, which had rejected Merck’s previous overtures, on Monday said it had agreed a $53 per share offer from the German healthcare and life sciences group that was superior to the all-stock deal it had struck with US rival Entegris in January. Merck will also assume Versum’s roughly $570m of net debt as part of the transaction. Merck had previously offered to pay $48 a share for Versum, before launching its hostile fight for the US chipmaker supplier.

  • Reuters12 days ago

    Merck KGaA raises offer for Versum Materials to $53 per share

    Versum Materials Inc said on Monday that Merck KGaA had raised its offer for the company to $53 per share from $48. Merck had launched a hostile $5.9 billion all-cash takeover offer for Versum last month ...

  • Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval
    Zacks16 days ago

    Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval

    Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.

  • Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval
    Zacks19 days ago

    Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

    Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.

  • Reuters22 days ago

    Versum opens books, begins to warm to rival suitor Merck KGaA

    "Merck’s proposal could reasonably be expected to result in a superior proposal," Versum, a maker of chemicals for the semiconductor industry, cited its board as saying in a statement on Friday. The board "has authorized Versum's management and its advisers to engage in further discussions with, and provide non-public information to, Merck," the statement added.

  • Reuters22 days ago

    Merck KGaA welcomes Versum's decision to talk, keeps tender going

    Merck KGaA on Friday welcomed Versum Materials to the negotiation table after the takeover target said it was willing to hold talks over Merck's unsolicited offer. "We welcome Versum's announcement ...

  • Reuters22 days ago

    UPDATE 1-Versum urges shareholders to reject Merck KGaA hostile bid

    Versum Materials Inc on Friday urged its shareholders to reject a hostile bid from Merck KGaA , but said it would engage with the German pharma group to determine if the offer is superior to its agreed merger with rival Entegris. Merck KGaA had on Tuesday launched a $5.9 billion all-cash takeover offer for Versum, the former speciality chemicals division of industrial gases group Air Products, to boost its presence in the semiconductor materials market and sideline a rival bidder. Versum has been opposed to Merck's bid since it was first proposed last month, saying it was committed to an all-share merger with U.S. rival Entegris agreed in January.

  • German Raider Gatecrashes $10 Billion U.S. Tie-Up
    Bloomberg24 days ago

    German Raider Gatecrashes $10 Billion U.S. Tie-Up

    To recap, Versum agreed to combine with rival Entegris Inc. in January. The market cheered, pushing Versum’s shares up 31 percent to $41, for a market value of $4.5 billion. Merck, capitalized at $48 billion, said a month later it wanted to buy Versum for $48 a share in cash, or $5.2 billion.

  • Merck KGaA goes hostile in $5.9 billion Versum takeover battle
    Reuters25 days ago

    Merck KGaA goes hostile in $5.9 billion Versum takeover battle

    German pharma group Merck KGaA launched a hostile $5.9 billion all-cash takeover offer for Versum Materials on Tuesday to boost its presence in the semiconductor materials market and sideline a rival bidder. Versum, the former speciality chemicals division of industrial gases group Air Products, has been opposed to Merck's unsolicited cash offer since it was first proposed last month, saying it was committed to an all-share merger with U.S. rival Entegris agreed in January. Merck kept its offer price unchanged at $48 per share on Tuesday.

  • Barrons.com25 days ago

    Merck KGaA Isn’t Giving Up on a Versum Takeover. It’s Going Hostile.

    Merck KGaA is trying to break up Versum’s planned merger with Entegris. It’s a bold step, but it isn't clear if Merck KGaA will be successful. Strangely enough, the $48 tender price is still below where Versum stock trades today.

  • Reuters25 days ago

    Merck KGaA makes takeover offer for Versum to shareholders

    Germany's Merck KGaA on Tuesday said it made a full takeover bid to shareholders of Versum Materials for $48 per share, after a previous deal proposal for the same price was rejected by the U.S. target's ...

  • Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study
    Zackslast month

    Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study

    Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.

  • Reuterslast month

    Merck KGaA calls on Versum investors to vote down Entegris merger

    FRANKFURT (Reuters) - Merck KGaA on Tuesday reiterated its recommendation to shareholders of its takeover target Versum to reject the electronic materials maker's planned merger with peer Entegris. In ...